Wave reports WVE-006 achieves protective AAT levels in Phase 1b/2a AATD trial

The RestorAATion-2 trial demonstrated that WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency (AATD), achieved clinically meaningful results. In the 200 mg biweekly cohort, the drug generated wild-type M-AAT protein at 64% of total AAT (matching the protective MZ heterozygous phenotype) and reduced harmful Z-AAT protein by 71%. The 400 mg monthly dosing showed similar efficacy with 13.6 µM total AAT, and editing effects persisted for at least three months after the last dose. These results suggest the therapy could address both lung and liver manifestations of AATD with convenient monthly subcutaneous dosing.

The trial demonstrated that WVE-006 restored the body's ability to dynamically increase AAT production during acute infections, a critical protective mechanism. Two patients in the 400 mg cohort showed AAT increases of 57.8% and 59.8% during mild upper respiratory infections. This dynamic response capability is important because the current standard of care (weekly intravenous augmentation therapy) may leave patients at risk if AAT levels fall too low during acute illness. The strong correlation between C-reactive protein and AAT elevation confirms this restored physiological response.

WVE-006 demonstrated a clean safety profile with no serious adverse events or liver toxicity, and all adverse events were mild to moderate. The sustained editing effect for at least three months after dosing supports convenient monthly subcutaneous administration, which would be a significant improvement over the current standard of weekly intravenous infusions. The RNA editing approach avoids the permanent genomic modifications associated with DNA editing and the liver inflammation issues associated with lipid nanoparticle delivery.

Wave is on track to receive FDA feedback on a potential accelerated approval pathway by mid-2026, which could expedite the drug's path to market. Additional data from the 600 mg monthly multidose cohort is expected in the second half of 2026. An accelerated approval pathway would be significant given that there are currently no approved therapies for AATD liver disease, and the only approved lung treatment requires weekly intravenous administration.

Wave disclosed positive interim results from its ongoing Phase 2 RestorAATion-2 trial evaluating WVE-006, an RNA editing therapy for alpha-1 antitrypsin deficiency. The company scheduled an investor call to present updated clinical data. This is a material development for Wave's lead pipeline asset, as positive trial data can influence regulatory pathway decisions and investor confidence in the program's commercial potential.

The company scheduled a same-day investor call to discuss the trial results and present detailed clinical data via a slide presentation to be posted on the investor relations website. This indicates management views the update as sufficiently material to warrant immediate investor communication.